Recent News
The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.Read Article
Wealth and Where you Live Influences Outcomes
Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and https://t.co/MyzWRx580R
Dr. John Cush @RheumNow ( View Tweet)
NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/jHqPxdG6f0
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/n7ku7LBkTM
Dr. John Cush @RheumNow ( View Tweet)
Survey: Upgrading & Maximizing the Classics (Urate Lowering Therapies, etc)
https://t.co/w6uzIlaeG7 https://t.co/HW09DVrMed
Dr. John Cush @RheumNow ( View Tweet)
What's New in Lyme Disease
JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.
https://t.co/jG09wc6gI8 https://t.co/rQBW6RIz5U
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Don't Presume on IL-1 in Gout
Dr. Richard Conway, Dublin, discusses the challenges of treating a 64 year-old male with a history of gout and CKD.
https://t.co/dgRyguHn18 https://t.co/Yakk7m7WsJ
Dr. John Cush @RheumNow ( View Tweet)
Updated Guidance for Artificial Intelligence Use in Medical Publications
JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This update provides specific information about what is permitted and not permitted, and what needs to be disclosed.
Read Article
"Be so good they can't ignore you." - Steve Martin https://t.co/lMRAY57rW9
Dr. John Cush @RheumNow ( View Tweet)
"The mediocre teacher tells. The good teacher explains. The superior teacher demonstrates. The great teacher inspires" - William Arthur Ward https://t.co/tvpFWtNR7K
Dr. John Cush @RheumNow ( View Tweet)
POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA
POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0
Dr. John Cush @RheumNow ( View Tweet)
Study of 364 Japanese myositis (IIM) pts - 42 (11.4%) had cancer-assoc myositis (CAM); 30/42 Dx w/in ±1 yr of IIM. CA risk incr ±3 yrs of IIM (SIR 2.54), highest 1st yr (SIR 8.66). 5 factors predicted CAM: TIF1γ +, ^CRP, dermatomyositis, older age, +FHx CA (AUC 0.86; sensitivity https://t.co/9ojTWTK5kO
Dr. John Cush @RheumNow ( View Tweet)
Congratulations to Dr. Edoardo Cipolletta (U Nottingham) - winner of Gout, Urate, and Crystal Deposition Disease Best PhD Thesis Award. Read his insightful interview on his reasearch on #gout. https://t.co/5i3hEV6PJX https://t.co/XV5trvEonW
Dr. John Cush @RheumNow ( View Tweet)
Substudy of 131 Still’s dz pts from the Autoinflammatory Dz (AIDA) registry. 38% underdosed w/ canakinumab (CAN) vs 62% appropriately dosed (300 mg q4wks or 4 mg/kg). Underdosed CAN had lower odds of long-term remission & D/C CAN (3.9% vs 19%) https://t.co/l94zB9NkKv https://t.co/D8FNUXS0nv
Dr. John Cush @RheumNow ( View Tweet)
CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (rituximab, ocrelizumab, ofatumumab, obinutuzumab, etc). West Nile virus was the most common arbovirus, but there are others; mortality up to 40%. Most arbovirus https://t.co/WWg41fsRgr
Dr. John Cush @RheumNow ( View Tweet)
Evaluating Inflammatory Joint Pain in Older Adults
Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for primary care clinicians, the tenets and clues ring true for all.
Read Article
From 1975 -2025, incidence of Kawasaki dz (KD) increased 16.1-fold in Japan, KD cases 15 032 and& 14 809 in 2023 & 2024, but during COVID #s dropped to 10 333 in 2022. KD #s rebounded after the COVID-19: Infants showed minimal changes, but kids 5-9 had the greatest increase https://t.co/j0BL2ZELXn
Dr. John Cush @RheumNow ( View Tweet)
Simple infographic on the MOA of deucravacitinib (Sotyktu). https://t.co/fXbxMAzvAE https://t.co/6IvA0Xz3m2
Dr. John Cush @RheumNow ( View Tweet)
MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG
Dr. John Cush @RheumNow ( View Tweet)
NP Salaries: in 7 specialties, NPs now avg >$150,000/yr, with the avg annual salary surpassing $137,000 in 2026 according toBureau of Labor Statistics. https://t.co/LlGFxkvEj5 https://t.co/h5bKsrnm4k
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Mentshlichkeit (8.7.2026)
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
TU: Systemic Burden of Gout Part 2 (24 plus)-
Methotrexate Safety Tips (7.31.2026)
Therapeutic Updates
Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Drs. Elizabeth Volkmann and Robert Suh explore the roles rheumatologists and radiologists play in diagnosing and monitoring autoimmune ILD and hear from a patient about her experience.
Read Post
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026.
Read Post
Poster Hall
